Inhibition of antibody-coated platelet destruction in patients with immune thrombocytopenic
purpura (ITP) is a well-known mechanism of treatment effect. A number of interventions that
would ameliorate the thrombocytopenic effect of ITP patient plasma when infused into
normal recipients were demonstrated in 1965. Subsequently, the antibody-coated chromium-
labeled red blood cell clearance study was developed to allow direct in vivo assessment of
Fc receptor (FcR) blockade. This was first demonstrated for corticosteroids but more …